Get notified when SGMT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Auditor Change (new) — KPMG replaced Deloitte as auditor in 2025 after Deloitte served since 2015; no explanation provided for the change.
Sagimet pivots MASH strategy to F4 combination trial, advances TVB-3567; Phase 3 monotherapy fate unclear
Filed March 11, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 12, 2025 · ~2 min read
Key Changes
-
high
Company shifted lead MASH program from Phase 3 monotherapy (F2-F3 patients, 1,800+ planned enrollment) to denifanstat-resmetirom combination for cirrhotic F4 patients. Phase 3 monotherapy trials (FASCINATE-3, FASCINIT) initiated Q4 2024 are no longer mentioned; no status update provided.
Business: Lead Program Pivot verify on EDGAR → -
high
Completed Phase 1 PK trial of denifanstat-resmetirom combination (Dec 2025) showing no drug interactions or safety signals. Phase 2 proof-of-concept in F4 MASH planned for H2 2026. Preclinical data showed 80% histological improvement vs 33% for denifanstat alone.
Business: Combination Program verify on EDGAR → -
high
Ascletis reported positive Phase 3 acne results (Jun 2025) meeting all endpoints; China NDA accepted (Dec 2025). Treatment success 33.2% vs 14.6% placebo (p<0.0001). Validates FASN inhibition in acne and creates near-term commercial milestone potential.
Business: Ascletis Acne Phase 3 verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade SGMT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify